Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

B. Paul, J. Minarik, F. Cottini, C. Gasparetto, J. Khouri, M. Gandhi, J. Hillengass, M. Levy, M. Liedtke, S. Manda, I. Sandhu, D. Sborov, I. Spicka, S. Usmani, M. Dong, L. Gu, C. Leung, P. Doshi, C. Chen, L. Pour

. 2025 ; 6 (3) : e70072. [pub] 20250606

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25014217

INTRODUCTION: Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. METHODS: This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR). RESULTS: ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade ≥ 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related. CONCLUSION: As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov as #NCT04892446.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014217
003      
CZ-PrNML
005      
20250905141454.0
007      
ta
008      
250701s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jha2.70072 $2 doi
035    __
$a (PubMed)40485906
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Paul, Barry $u Atrium Health Levine Cancer Institute Wake Forest University School of Medicine Charlotte North Carolina USA $1 https://orcid.org/0000000327028225
245    10
$a Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma / $c B. Paul, J. Minarik, F. Cottini, C. Gasparetto, J. Khouri, M. Gandhi, J. Hillengass, M. Levy, M. Liedtke, S. Manda, I. Sandhu, D. Sborov, I. Spicka, S. Usmani, M. Dong, L. Gu, C. Leung, P. Doshi, C. Chen, L. Pour
520    9_
$a INTRODUCTION: Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. METHODS: This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR). RESULTS: ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade ≥ 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related. CONCLUSION: As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov as #NCT04892446.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Minarik, Jiri $u Fakultni Nemocnice Olomouc Olomouc Czech Republic
700    1_
$a Cottini, Francesca $u The Ohio State University Columbus Ohio USA $1 https://orcid.org/0000000186767840
700    1_
$a Gasparetto, Cristina $u Duke Cancer Institute Durham North Carolina USA
700    1_
$a Khouri, Jack $u Cleveland Clinic Cleveland Ohio USA $1 https://orcid.org/0000000224736528
700    1_
$a Gandhi, Mitul $u US Oncology Site, Virginia Cancer Specialists Fairfax Virginia USA
700    1_
$a Hillengass, Jens $u Roswell Park Cancer Institute Buffalo New York USA
700    1_
$a Levy, Moshe $u Baylor University Medical Center Dallas Texas USA
700    1_
$a Liedtke, Michaela $u Stanford Cancer Center Palo Alto California USA
700    1_
$a Manda, Sudhir $u Arizona Oncology Associates Tucson Arizona USA
700    1_
$a Sandhu, Irwindeep $u Cross Cancer Institute Edmonton Alberta Canada
700    1_
$a Sborov, Douglas $u Huntsman Cancer Institute at the University of Utah Salt Lake City Utah USA $1 https://orcid.org/0000000342682698
700    1_
$a Spicka, Ivan $u Charles University Hospital Kralovske Vinohrady Prague Czech Republic
700    1_
$a Usmani, Saad $u Memorial Sloan-Kettering Cancer Center New York New York USA
700    1_
$a Dong, Mei $u Gilead Sciences, Inc Foster City California USA
700    1_
$a Gu, Lin $u Gilead Sciences, Inc Foster City California USA
700    1_
$a Leung, Carmen $u Gilead Sciences, Inc Foster City California USA
700    1_
$a Doshi, Parul $u Gilead Sciences, Inc Foster City California USA
700    1_
$a Chen, Christine $u Princess Margaret Cancer Centre Toronto Ontario Canada $1 https://orcid.org/0000000295283669
700    1_
$a Pour, Ludek $u University Hospital Brno Brno Czech Republic
773    0_
$w MED00209731 $t EJHaem $x 2688-6146 $g Roč. 6, č. 3 (2025), s. e70072
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40485906 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141442 $b ABA008
999    __
$a ok $b bmc $g 2388000 $s 1251337
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 6 $c 3 $d e70072 $e 20250606 $i 2688-6146 $m EJHaem $n EJHaem $x MED00209731
LZP    __
$a Pubmed-20250701

Najít záznam

Citační ukazatele

Možnosti archivace